Twist Bioscience FY26 Q2 net loss widens to $44 million; revenue rises 19% to $110.7 million

Twist Bioscience

Twist Bioscience

TWST

0.00
  • Twist Bioscience reported fiscal Q2 revenue rose 19% to $110.7 million.
  • Net loss widened to $44 million, or $0.71 per share.
  • Gross margin improved 2 percentage points to 51.6%, while adjusted EBITDA loss narrowed to $13.3 million.
  • DSPS revenue climbed 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million.
  • Raised fiscal 2026 revenue outlook to $442 million-$447 million, reaffirming adjusted EBITDA breakeven in fiscal Q4.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000037), on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.